EWTX logo

Edgewise Therapeutics (EWTX) Cash From Financing

Annual CFF

$249.25 M
+$196.09 M+368.82%

December 31, 2024


Summary


Performance

EWTX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherEWTXcash flowmetrics:

Quarterly CFF

$2.90 M
-$438.00 K-13.14%

December 31, 2024


Summary


Performance

EWTX Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherEWTXcash flowmetrics:

TTM CFF

$249.25 M
-$50.09 M-16.73%

December 31, 2024


Summary


Performance

EWTX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherEWTXcash flowmetrics:

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

EWTX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+368.8%-13.1%-16.7%
3 y3 years+33.7%+1472.0%+10000.0%
5 y5 years+905.0%+1472.0%+10000.0%

EWTX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+368.8%-98.8%+1055.5%-16.7%>+9999.0%
5 y5-yearat high+905.0%-98.8%+423.1%-18.9%>+9999.0%
alltimeall timeat high+905.0%-98.8%+423.1%-18.9%>+9999.0%

Edgewise Therapeutics Cash From Financing History

DateAnnualQuarterlyTTM
Dec 2024
$249.25 M(+368.8%)
$2.90 M(-13.1%)
$249.25 M(-16.7%)
Sep 2024
-
$3.33 M(+70.7%)
$299.35 M(+1.2%)
Jun 2024
-
$1.95 M(-99.2%)
$295.80 M(+0.5%)
Mar 2024
-
$241.07 M(+355.0%)
$294.22 M(+453.4%)
Dec 2023
$53.17 M(-59.0%)
$52.99 M(<-9900.0%)
$53.17 M(<-9900.0%)
Sep 2023
-
-$211.00 K(-157.2%)
-$124.00 K(-100.1%)
Jun 2023
-
$369.00 K(+1657.1%)
$129.78 M(+0.1%)
Mar 2023
-
$21.00 K(-106.9%)
$129.59 M(-0.0%)
Dec 2022
$129.64 M
-$303.00 K(-100.2%)
$129.64 M(-0.5%)
Sep 2022
-
$129.69 M(>+9900.0%)
$130.24 M(>+9900.0%)
DateAnnualQuarterlyTTM
Jun 2022
-
$179.00 K(+145.2%)
$582.00 K(-218.1%)
Mar 2022
-
$73.00 K(-75.1%)
-$493.00 K(-100.3%)
Dec 2021
$186.38 M(+55.0%)
$293.00 K(+691.9%)
$186.38 M(-33.7%)
Sep 2021
-
$37.00 K(-104.1%)
$281.09 M(-8.2%)
Jun 2021
-
-$896.00 K(-100.5%)
$306.20 M(-0.3%)
Mar 2021
-
$186.95 M(+96.8%)
$307.23 M(+155.4%)
Dec 2020
$120.28 M(+385.0%)
$95.00 M(+277.9%)
$120.28 M(+375.8%)
Sep 2020
-
$25.14 M(>+9900.0%)
$25.28 M(>+9900.0%)
Jun 2020
-
$135.00 K(>+9900.0%)
$135.00 K(>+9900.0%)
Mar 2020
-
$0.00
$0.00
Dec 2019
$24.80 M
-
-

FAQ

  • What is Edgewise Therapeutics annual cash flow from financing activities?
  • What is the all time high annual CFF for Edgewise Therapeutics?
  • What is Edgewise Therapeutics annual CFF year-on-year change?
  • What is Edgewise Therapeutics quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Edgewise Therapeutics?
  • What is Edgewise Therapeutics quarterly CFF year-on-year change?
  • What is Edgewise Therapeutics TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Edgewise Therapeutics?
  • What is Edgewise Therapeutics TTM CFF year-on-year change?

What is Edgewise Therapeutics annual cash flow from financing activities?

The current annual CFF of EWTX is $249.25 M

What is the all time high annual CFF for Edgewise Therapeutics?

Edgewise Therapeutics all-time high annual cash flow from financing activities is $249.25 M

What is Edgewise Therapeutics annual CFF year-on-year change?

Over the past year, EWTX annual cash flow from financing activities has changed by +$196.09 M (+368.82%)

What is Edgewise Therapeutics quarterly cash flow from financing activities?

The current quarterly CFF of EWTX is $2.90 M

What is the all time high quarterly CFF for Edgewise Therapeutics?

Edgewise Therapeutics all-time high quarterly cash flow from financing activities is $241.07 M

What is Edgewise Therapeutics quarterly CFF year-on-year change?

Over the past year, EWTX quarterly cash flow from financing activities has changed by -$438.00 K (-13.14%)

What is Edgewise Therapeutics TTM cash flow from financing activities?

The current TTM CFF of EWTX is $249.25 M

What is the all time high TTM CFF for Edgewise Therapeutics?

Edgewise Therapeutics all-time high TTM cash flow from financing activities is $307.23 M

What is Edgewise Therapeutics TTM CFF year-on-year change?

Over the past year, EWTX TTM cash flow from financing activities has changed by -$50.09 M (-16.73%)